for adults with paroxysmal nocturnal hemoglobinuria (PNH) as well as its strategic priorities for continued growth. “SYFOVRE is the market-leading treatment for GA, with more than 120% net sales ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

The "Paroxysmal Supraventricular Tachycardia Market"is anticipated to increase from USD xxx billion in 2023 to USD xxx billion by 2031, with a strong compound annual growth rate (CAGR) of xxx% from ...

Shinsegae Group announced on the 21st that Chairman Chung Yong-jin, who visited the United States to attend President Trump's ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

On this page, we're recording the regulatory progress of in-market products ... by the agency in 2023 as a treatment for paroxysmal nocturnal hemoglobinuria, winning the title of the first ...

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year.

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Net income came in at $2.9 billion, compared with a net loss of $1.8 billion a year ago. On a per-share basis, Citi earned $1.34. Analysts polled by FactSet forecasted $1.22. Revenue rose 12% to ...

JPMorgan CFO Jeremy Barnum acknowledged on the post-earnings call with analysts that there was "tension" between macro risks and uncertainties and the optimism embedded in asset prices and ...

and market demand. The investment landscape in 2025 offers several promising opportunities in high-growth sectors. While market volatility continues to be a challenge, certain areas stand out for ...